Becton Dickinson Ventures

Becton Dickinson Ventures is the corporate venture capital entity of BD, a global medical technology manufacturer headquartered in Franklin Lakes, New Jersey. The fund concentrates on breakthrough innovations in diagnostic accuracy and medication management, aligning with BD’s commercial focus on medical devices, MedTech, and diagnostics. As a strategic investor, the team values both financial returns and access to technologies that complement or extend BD’s existing product portfolio. AI focus is not formally indicated, though AI-enabled diagnostics and medication safety tools naturally align with the stated thesis.

Investments occur at seed and Series A stages with check sizes between $1M and $5M. Activity is global by virtue of BD’s international footprint, though specific geographic priorities are not publicly detailed. The fund typically participates as a strategic co-investor alongside traditional MedTech, diagnostics, or healthcare investors, contributing technical, regulatory, and commercial expertise from the parent company. Companies that fit best are often working at the intersection of hardware, software, and clinical workflow.

For founders, the strongest pitch frames the company as a complement to or extension of BD’s diagnostic or medication management platforms, with clear regulatory pathway and clinical evidence plans. AI should be positioned as embedded intelligence inside devices or workflows rather than purely as a software offering. Limited public information is available on partner-level deal sourcing, so introductions through BD business unit leaders, MedTech investors, and clinical key opinion leaders are the most reliable channels.